Cipla is currently trading at Rs. 644.75, up by 2.15 points or 0.33% from its previous closing of Rs. 642.60 on the BSE.
The scrip opened at Rs. 643.00 and has touched a high and low of Rs. 645.70 and Rs. 639.05 respectively. So far 23076 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 752.45 on 10-Mar-2015 and a 52 week low of Rs. 572.00 on 15-Jun-2015.
Last one week high and low of the scrip stood at Rs. 649.50 and Rs. 633.00 respectively. The current market cap of the company is Rs. 51727.98 crore.
The promoters holding in the company stood at 36.79% while Institutions and Non-Institutions held 34.24% and 26.63% respectively.
Cipla has inked an investment pact with FIL Capital Investments (Mauritius) II for its consumer healthcare business. The investment is subject to approvals from the Foreign Investment Promotion Board (FIPB) and the Competition Commission of India (CCI), and the transfer of Cipla’s consumer healthcare business to Cipla Health.
In July, Cipla’s board had approved an investment by Fidelity Growth Partners India and US-based Fidelity Biosciences, through FIL Capital Investments (Mauritius) II or its affiliates in its recently launched consumer healthcare business.
Cipla has emerged as one of the most respected pharmaceutical names in India as well as across more than 150 countries. Its portfolio includes 1500 plus products across therapeutic categories with one quality standard globally.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1515.00 |
Dr. Reddys Lab | 6080.25 |
Cipla | 1565.50 |
Zydus Lifesciences | 1110.95 |
Lupin | 1601.00 |
View more.. |